Chinanews.com, Beijing, September 24, electrical myocardial infarction is a myocardial necrosis caused by acute and persistent coronary ischemia and hypoxia. The risk of recurrence after myocardial infarction is high.
Kong Lingzhi, chairman of the Health Communication Branch of the Chinese Preventive Medicine Association and former deputy director of the Department of Disease Control and Prevention of the Ministry of Health, said that the prevalence of cardiovascular diseases in China is on the rise, and the management of low-density lipoprotein cholesterol is essential to prevent recurrent myocardial infarction. .
Recently, the "China Health Knowledge Dissemination Incentive Program" project jointly initiated and directed by the National Health Commission for Disease Control, China Health Education Center and the Office of the China Association for Records, organized research and discussion by experts from all walks of life, and released the "Cholesterol Reaching Standards, Preventing Renewed Heart The "Core Reminder of Infarction" is designed to help patients with myocardial infarction pay attention to cholesterol standards and prevent recurrent myocardial infarction.
Professor Ma Changsheng, appointed chairman of the Cardiovascular Branch of the Chinese Medical Association and director of the Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, said that the patient suffered a myocardial infarction, stroke or death from cardiovascular disease within 1 year after the first myocardial infarction. The average risk is 20%.
Elevated low-density lipoprotein cholesterol (LDL-C) is the most important risk factor for recurrence of myocardial infarction.
Therefore, patients with myocardial infarction should follow the doctor’s advice and strictly control the low-density lipoprotein cholesterol and other related indicators at a reasonable level.
According to reports, there are different target values for low-density lipoprotein cholesterol levels in different populations with cardiovascular disease risk.
The target value of low-density lipoprotein cholesterol for patients with myocardial infarction is lower.
The vast majority of patients with myocardial infarction belong to the ultra-high risk group of atherosclerotic cardiovascular disease (ASCVD).
The ultra-high-risk population should be more strictly managed cholesterol levels, and their low-density lipoprotein cholesterol target value should be reduced to 1.4mmol/L or less, and should be reduced by at least 50% compared to the level before lipid-lowering drugs, and both should meet the standards.
For patients with 2 or more adverse cardiovascular events within 2 years, it is possible to consider reducing LDL cholesterol to less than 1.0mmol/L, which is more than 50% lower than before using lipid-lowering drugs.
Since the reference range of the normal value on the blood lipid examination test sheet is for ordinary people, patients with myocardial infarction cannot relax the management of low-density lipoprotein cholesterol based on the test sheet showing normal, and must achieve low-density lipoprotein cholesterol under the guidance of a doctor Double reach the standard to prevent the occurrence of myocardial infarction again.
Professor Chen Weiwei from Fuwai Hospital of the Chinese Academy of Medical Sciences pointed out that patients with myocardial infarction should receive standardized treatment and interventions to improve their lifestyle, and put forward the following suggestions:
One is to test blood lipids regularly.
Patients with myocardial infarction should measure their blood lipids every 3-6 months, and control the low-density lipoprotein cholesterol in blood lipids below the target level under the guidance of a doctor.
The second is to maintain a healthy lifestyle.
Patients with myocardial infarction should scientifically manage their meals, quit smoking and alcohol, control their weight and waist circumference, and maintain appropriate physical activity under the guidance of a doctor.
The third is to adhere to standardized treatment.
The risk of recurrence within 1 year after the occurrence of myocardial infarction is very high.
Patients with myocardial infarction should undergo standardized clinical treatment on the basis of improving their lifestyle.
Especially the ultra-high-risk population should achieve both low-density lipoprotein cholesterol control standards as soon as possible and continue.
The fourth is the joint management of blood lipids, blood pressure and blood sugar.
Hypertension, diabetes, etc. will increase the risk of recurring myocardial infarction.
Patients with myocardial infarction must carry out strict management of the "three highs" at the same time to minimize the risk of recurrent myocardial infarction.
(Finish)